Skin tolerability of transdermal patches

被引:15
|
作者
Wohlrab, Johannes [1 ,2 ]
Kreft, B. [1 ]
Tamke, B. [3 ]
机构
[1] Univ Halle Wittenberg, Dept Dermatol & Venereol, D-06097 Halle, Saale, Germany
[2] Univ Halle Wittenberg, Inst Appl Dermatopharm, D-06097 Halle, Saale, Germany
[3] Univ Halle Wittenberg, Dept Anaesthesiol & Intens Care, D-06097 Halle, Saale, Germany
关键词
drug delivery; intolerance; safety and tolerability; transdermal patch systems; ALOE-VERA GEL; DRUG-DELIVERY; DOUBLE-BLIND; BARBADENSIS MILLER; THERAPEUTIC SYSTEM; PHENOLIC-COMPOUNDS; PHASE-III; EFFICACY; BUPRENORPHINE; STIMULATION;
D O I
10.1517/17425247.2011.574689
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Transdermal patch systems are an effective method of administering active ingredients through the skin, with considerable advantages over other drug delivery routes, for example, maintenance of constant plasma drug levels and avoidance of first-pass metabolism. However, repeated epicutaneous application may be associated with local skin reactions. Areas covered: This review addresses current issues regarding the effective/safe use of transdermal patch systems, and provides a critical analysis of the addition of 'skin-caring' ingredients to patch systems. Effective use of transdermal systems includes choosing an appropriate body area for application, maintaining regular skin care regimens before application and not replacing a patch in the same area (rotation) within 7 days. Another strategy, developed in an attempt to improve the tolerability of transdermal systems, is the addition of assumed 'skin-caring' ingredients (e.g., Aloe Vera) to patch systems. However, at present there is neither proof nor clinical evidence of any benefit. On the contrary, plant-derived ingredients might be associated with allergenic potential. Expert opinion: Transdermal systems are generally well tolerated; physicians must adequately inform patients of the most effective ways to use these formulations for maximum therapeutic benefit, while minimising local adverse events. Skin-caring agents, including Aloe Vera, cannot be recommended until well-controlled clinical trials with standardised extracts are available.
引用
收藏
页码:939 / 948
页数:10
相关论文
共 50 条
  • [31] Generic Transdermal Patches for Chronic Pain
    不详
    NURSE PRACTITIONER, 2005, 30 (08): : 55 - 55
  • [32] DESIGN AND EVALUATION OF DEXAMETHASONE TRANSDERMAL PATCHES
    SINGH, P
    ROBERTS, MS
    NEW ZEALAND MEDICAL JOURNAL, 1990, 103 (889) : 222 - 222
  • [33] Transdermal patches: history, development and pharmacology
    Pastore, Michael N.
    Kalia, Yogeshvar N.
    Horstmann, Michael
    Roberts, Michael S.
    BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (09) : 2179 - 2209
  • [34] Transdermal patches: Not just for control freaks?
    Foreman, PB
    Jacobson, SH
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U541 - U541
  • [35] Transdermal drug delivery and patches—An overview
    Bird, David
    Ravindra, Nuggehalli M.
    Medical Devices and Sensors, 2020, 3 (06):
  • [36] SUPPRESSION OF OVULATION BY TRANSDERMAL ESTRADIOL PATCHES
    WATSON, NR
    STUDD, JWW
    RIDDLE, AF
    SAVVAS, M
    BRITISH MEDICAL JOURNAL, 1988, 297 (6653): : 900 - 901
  • [37] Transdermal fentanyl patches in small animals
    Hofmeister, Erik H.
    Egger, Christine M.
    JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION, 2004, 40 (06) : 468 - 478
  • [38] Wearable patches for transdermal drug delivery
    He, Jiahui
    Zhang, Yuyue
    Yu, Xinge
    Xu, Chenjie
    ACTA PHARMACEUTICA SINICA B, 2023, 13 (06) : 2298 - 2309
  • [39] Wearable patches for transdermal drug delivery
    Jiahui He
    Yuyue Zhang
    Xinge Yu
    Chenjie Xu
    Acta Pharmaceutica Sinica B, 2023, (06) : 2298 - 2309
  • [40] Nicotine transdermal patches and pregnancy - Reply
    Schroeder, DR
    Offord, KP
    Ogburn, P
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 183 (03) : 778 - 779